Panel Discussion: Addressing the Shortcomings of Developing NSCLC-Targeted Therapies

Time: 8:50 am
day: Day One


  • Patient population response differences and how to overcome these
  • What design elements are most optimal to achieve clinical benefit?
  • The push to early disease: what will this entail?
  • How can the mechanism of action be predicted for each patient and thus inform dosing strategies?